These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32076459)

  • 1. Identification of Protein Expression Changes in Hepatocellular Carcinoma through iTRAQ.
    Zhang Y; Ying X; Zhao Q; Ma J; Zhang D; He C; Han S
    Dis Markers; 2020; 2020():2632716. PubMed ID: 32076459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative proteomics reveals FLNC as a potential progression marker for the development of hepatocellular carcinoma.
    Qi Y; Xu F; Chen L; Li Y; Xu Z; Zhang Y; Wei W; Su N; Zhang T; Fan F; Wang X; Qin X; Zhang L; Liu Y; Xu P
    Oncotarget; 2016 Oct; 7(42):68242-68252. PubMed ID: 27626164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative proteomic analysis identified paraoxonase 1 as a novel serum biomarker for microvascular invasion in hepatocellular carcinoma.
    Huang C; Wang Y; Liu S; Ding G; Liu W; Zhou J; Kuang M; Ji Y; Kondo T; Fan J
    J Proteome Res; 2013 Apr; 12(4):1838-46. PubMed ID: 23442176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum fucosylated paraoxonase 1 as a potential glycobiomarker for clinical diagnosis of early hepatocellular carcinoma using ELISA Index.
    Zhang S; Jiang K; Zhang Q; Guo K; Liu Y
    Glycoconj J; 2015 May; 32(3-4):119-25. PubMed ID: 25702281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peroxiredoxin2 downregulation enhances hepatocellular carcinoma proliferation and migration, and is associated with unfavorable prognosis in patients.
    Bai B; Lin Y; Hu J; Wang H; Li L; Zhao S; Zhang J; Meng W; Yue P; Bai Z; Li X
    Oncol Rep; 2019 Mar; 41(3):1539-1548. PubMed ID: 30747220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative proteomic analysis in HCV-induced HCC reveals sets of proteins with potential significance for racial disparity.
    Dillon ST; Bhasin MK; Feng X; Koh DW; Daoud SS
    J Transl Med; 2013 Oct; 11():239. PubMed ID: 24283668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-depth proteomic analysis of tissue interstitial fluid for hepatocellular carcinoma serum biomarker discovery.
    Zhang J; Hao N; Liu W; Lu M; Sun L; Chen N; Wu M; Zhao X; Xing B; Sun W; He F
    Br J Cancer; 2017 Nov; 117(11):1676-1684. PubMed ID: 29024941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative Proteomics Analysis of Tissue Interstitial Fluid for Identification of Novel Serum Candidate Diagnostic Marker for Hepatocellular Carcinoma.
    Sun W; Xing B; Guo L; Liu Z; Mu J; Sun L; Wei H; Zhao X; Qian X; Jiang Y; He F
    Sci Rep; 2016 May; 6():26499. PubMed ID: 27216119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reveal the molecular signatures of hepatocellular carcinoma with different sizes by iTRAQ based quantitative proteomics.
    Wang Y; Liu H; Liang D; Huang Y; Zeng Y; Xing X; Xia J; Lin M; Han X; Liao N; Liu X; Liu J
    J Proteomics; 2017 Jan; 150():230-241. PubMed ID: 27693406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive analyses of competing endogenous RNA networks reveal potential biomarkers for predicting hepatocellular carcinoma recurrence.
    Yan P; Huang Z; Mou T; Luo Y; Liu Y; Zhou B; Cao Z; Wu Z
    BMC Cancer; 2021 Apr; 21(1):436. PubMed ID: 33879119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of survival-related predictors in hepatocellular carcinoma through integrated genomic, transcriptomic, and proteomic analyses.
    Dong F; Yang Q; Wu Z; Hu X; Shi D; Feng M; Li J; Zhu L; Jiang S; Bao Z
    Biomed Pharmacother; 2019 Jun; 114():108856. PubMed ID: 30981109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteome Differences between Hepatitis B Virus Genotype-B- and Genotype-C-Induced Hepatocellular Carcinoma Revealed by iTRAQ-Based Quantitative Proteomics.
    Wei D; Zeng Y; Xing X; Liu H; Lin M; Han X; Liu X; Liu J
    J Proteome Res; 2016 Feb; 15(2):487-98. PubMed ID: 26709725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of novel diagnostic and prognostic biomarkers for hepatocellular carcinoma.
    Wang F; Dong J; Zhang Y; Yue S; Guo H; Liang P; Zhou Y; Wei Y; Zhai W; Gao J
    Oncol Rep; 2020 Jan; 43(1):87-98. PubMed ID: 31789422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of EWSR1 (Ewing sarcoma breakpoint region 1/EWS RNA binding protein 1) predicts poor survival in patients with hepatocellular carcinoma.
    Jiang W; Wu T; Shi X; Xu J
    Bioengineered; 2021 Dec; 12(1):7941-7949. PubMed ID: 34612781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Potential Biomarkers From Hepatocellular Carcinoma With MT1 Deletion.
    Zhang R; Huang M; Wang H; Wu S; Yao J; Ge Y; Lu Y; Hu Q
    Pathol Oncol Res; 2021; 27():597527. PubMed ID: 34257549
    [No Abstract]   [Full Text] [Related]  

  • 16. Serum Irisin Predicts Posthepatectomy Complications in Patients with Hepatocellular Carcinoma.
    Zhang J; Ke M; Ren Y; Bi J; Du Z; Zhang M; Wang Y; Zhang L; Wu Z; Lv Y; Wu R
    Dis Markers; 2019; 2019():9850191. PubMed ID: 31976024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying 13 Hub Genes Associated with Progression and Prognosis of Hepatocellular Carcinoma with Weighted Gene Co-Expression Network Analysis.
    Liu Y; Cheng R; Chang Q; Wu Y; Liu C; Liu Y; Wu X; Cheng L; Hu L; Yin J
    Crit Rev Eukaryot Gene Expr; 2021; 31(4):59-69. PubMed ID: 34587436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exosomal microRNAs as potential biomarkers for cancer cell migration and prognosis in hepatocellular carcinoma patient-derived cell models.
    Yu LX; Zhang BL; Yang Y; Wang MC; Lei GL; Gao Y; Liu H; Xiao CH; Xu JJ; Qin H; Xu XY; Chen ZS; Zhang DD; Li FG; Zhang SG; Liu R
    Oncol Rep; 2019 Jan; 41(1):257-269. PubMed ID: 30542726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Candidate Biomarkers in Malignant Ascites from Patients with Hepatocellular Carcinoma by iTRAQ-Based Quantitative Proteomic Analysis.
    Zhang J; Liang R; Wei J; Ye J; He Q; ChunlingYuan ; Ye J; Li Y; Liu Z; Lin Y
    Biomed Res Int; 2018; 2018():5484976. PubMed ID: 30345303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of serum paraoxonase/arylesterase 1 and antithrombin-III is a promising non-invasion biomarker for discrimination of AFP-negative HCC versus liver cirrhosis patients.
    Cao X; Cao Z; Ou C; Zhang L; Chen Y; Li Y; Zhu B; Shu H
    Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101583. PubMed ID: 33756265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.